Fuji Pharma Co., Ltd. (TYO:4554)
Japan
· Delayed Price · Currency is JPY 1,323.00
+6.00 (0.46%)
Jun 13, 2025, 3:30 PM JST
Fuji Pharma Cash Flow Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2015 - 2019 |
| Net Income | 4,000 | 8,276 | 4,399 | 3,723 | 3,371 | 2,918 | Upgrade
|
| Depreciation & Amortization | 3,957 | 3,680 | 3,023 | 2,745 | 2,106 | 2,057 | Upgrade
|
| Loss (Gain) From Sale of Assets | 394 | - | 4 | 1 | 33 | 69 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -3,118 | - | - | -153 | - | Upgrade
|
| Other Operating Activities | -2,161 | -1,027 | -941 | -1,504 | -915 | -726 | Upgrade
|
| Change in Accounts Receivable | -407 | -1,997 | -3,705 | -549 | -174 | 1,203 | Upgrade
|
| Change in Inventory | -1,548 | 1,552 | -3,395 | -3,618 | -1,340 | -23 | Upgrade
|
| Change in Accounts Payable | 1,525 | -1,640 | -652 | 447 | 2,038 | -1,102 | Upgrade
|
| Change in Other Net Operating Assets | 967 | -1,575 | 3,184 | -1,903 | 1,027 | 1,374 | Upgrade
|
| Operating Cash Flow | 6,727 | 4,151 | 1,917 | -658 | 5,993 | 5,770 | Upgrade
|
| Operating Cash Flow Growth | - | 116.54% | - | - | 3.86% | -17.98% | Upgrade
|
| Capital Expenditures | -1,559 | -2,778 | -3,327 | -5,097 | -3,789 | -2,322 | Upgrade
|
| Sale of Property, Plant & Equipment | 2 | 2 | 10 | 1,383 | 1,673 | 26 | Upgrade
|
| Sale (Purchase) of Intangibles | -2,349 | -1,594 | -570 | -7,326 | -107 | -293 | Upgrade
|
| Investment in Securities | - | 5,356 | - | - | 189 | - | Upgrade
|
| Other Investing Activities | -1,973 | -2,644 | -1,353 | -231 | -311 | -27 | Upgrade
|
| Investing Cash Flow | -5,879 | -1,658 | -5,240 | -11,271 | -2,345 | -2,616 | Upgrade
|
| Short-Term Debt Issued | - | 4,000 | 3,000 | 1,300 | 6,000 | 1,000 | Upgrade
|
| Long-Term Debt Issued | - | - | 2,985 | 7,300 | 1,000 | 4,000 | Upgrade
|
| Total Debt Issued | 13,486 | 4,000 | 5,985 | 8,600 | 7,000 | 5,000 | Upgrade
|
| Long-Term Debt Repaid | - | -5,210 | -2,740 | -2,140 | -1,756 | -3,140 | Upgrade
|
| Total Debt Repaid | -7,700 | -5,210 | -2,740 | -2,140 | -1,756 | -3,140 | Upgrade
|
| Net Debt Issued (Repaid) | 5,786 | -1,210 | 3,245 | 6,460 | 5,244 | 1,860 | Upgrade
|
| Issuance of Common Stock | 226 | 55 | - | - | 11 | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | -9,405 | - | Upgrade
|
| Dividends Paid | -1,087 | -972 | -899 | -729 | -807 | -904 | Upgrade
|
| Other Financing Activities | -612 | 1,692 | -431 | -637 | -478 | -506 | Upgrade
|
| Financing Cash Flow | 4,313 | -435 | 1,915 | 5,094 | -5,435 | 450 | Upgrade
|
| Foreign Exchange Rate Adjustments | 158 | 202 | 185 | 183 | -55 | -56 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -2 | - | 2 | -1 | - | -1 | Upgrade
|
| Net Cash Flow | 5,317 | 2,260 | -1,221 | -6,653 | -1,842 | 3,547 | Upgrade
|
| Free Cash Flow | 5,168 | 1,373 | -1,410 | -5,755 | 2,204 | 3,448 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | -36.08% | -35.36% | Upgrade
|
| Free Cash Flow Margin | 10.58% | 2.98% | -3.45% | -16.25% | 6.48% | 10.20% | Upgrade
|
| Free Cash Flow Per Share | 212.32 | 56.48 | -58.02 | -236.90 | 82.03 | 110.66 | Upgrade
|
| Cash Interest Paid | 252 | 194 | 104 | 82 | 59 | 41 | Upgrade
|
| Cash Income Tax Paid | 2,164 | 1,026 | 946 | 1,498 | 911 | 723 | Upgrade
|
| Levered Free Cash Flow | 1,340 | 599.13 | -4,258 | -11,724 | 1,392 | 3,078 | Upgrade
|
| Unlevered Free Cash Flow | 1,500 | 721.63 | -4,182 | -11,676 | 1,425 | 3,102 | Upgrade
|
| Change in Net Working Capital | 1,513 | 1,012 | 5,720 | 4,359 | -1,122 | -1,697 | Upgrade
|
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.